Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models

1 Oct 2021

Abstract excerpt

Functional precision medicine aims to match individual cancer patients to optimal treatment through ex vivo drug susceptibility testing on patient-derived cells. However, few functional diagnostic assays have been validated against patient outcomes at scale because of limitations of such assays. Here, we describe a high-throughput assay that detects subtle changes in the mass of individual drug-treated cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34610309
DOI: 10.1016/j.celrep.2021.109788

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere modelsPMID 34610309Read ↗

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkersSemantic proximity Read ↗

Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?Semantic proximity Read ↗

Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivitySemantic proximity Read ↗

Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastomaSemantic proximity Read ↗

Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastomaSemantic proximity Read ↗

Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assaySemantic proximity Read ↗

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastomaSemantic proximity Read ↗

Temozolomide in the Era of Precision MedicineSemantic proximity Read ↗

A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem CellsSemantic proximity Read ↗

Three-dimensional patient-derived models of glioblastoma retain intra-tumoral heterogeneitySemantic proximity Read ↗

Metabolic-imaging of human glioblastoma live tumors: a new precision-medicine approach to predict tumor treatment response earlySemantic proximity Read ↗

A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.